시장보고서
상품코드
1436555

세계의 골다공증 치료제 시장 보고서(2024년)

Osteoporosis Drugs Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

골다공증 치료제 시장 규모는 향후 몇 년 동안 꾸준히 성장할 것으로 예상됩니다. 2028년까지 연평균 3.3%의 복합 성장률(CAGR)로 142억 달러에 달할 것으로 예상됩니다. 예상되는 성장은 인구 고령화의 지속적인 추세, 치료 옵션의 발전, 남성의 뼈 건강에 대한 관심 증가, 환자 교육, 세계 보건 정책에 의해 촉진될 것으로 예상됩니다. 주요 동향으로는 개인 맞춤형 의료, 병용 요법 탐색, 골절 예방에 대한 강조, 새로운 약물 표적에 대한 연구 및 개발, 약물 개발을 위한 공동의 노력 등이 있습니다.

골다공증 유병률의 증가는 골다공증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 골다공증은 골밀도와 골량의 감소 또는 뼈의 질과 구조의 변화를 특징으로하는 뼈 질환으로, 종종 칼슘 섭취 감소와 관련이 있습니다. 골다공증 치료제는 이 질환에 걸린 사람들의 골밀도를 높이고 골절을 예방하는 데 중요한 역할을 합니다. 예를 들어, 2022년 5월 기준 미국 생명공학 기업 암젠(Amgen)의 통계에 따르면 골다공증은 미국에서 연간 약 150만 건의 골절을 유발하고 관련 비용은 190억 달러에 달하는 것으로 나타났습니다. 또한 골다공증으로 인한 연간 골절 건수는 2018년부터 2040년까지 190만 건에서 320만 건으로 68% 증가할 것으로 예측됩니다. 따라서 골다공증 유병률의 급격한 증가는 골다공증 치료제 시장의 성장을 촉진하는 중요한 요인이 되고 있습니다.

고령화 인구의 증가는 가까운 미래에 골다공증 치료제 시장 성장의 중요한 원동력이 될 것으로 예상됩니다. 인구 고령화는 주로 출산율 감소와 평균 수명 연장의 영향을 받아 인구의 평균 연령이 상승하는 것을 의미합니다. 골다공증의 위험은 골밀도의 자연적 감소로 인해 나이가 들어감에 따라 증가하는 것으로 알려져 있습니다. 노인 인구의 증가로 인해 골다공증 치료제에 대한 수요가 증가하고 있습니다. 예를 들어, 스위스에 본사를 둔 정부 간 기구인 세계보건기구(WHO)의 데이터에 따르면, 2022년 전 세계 60세 이상 인구는 10억 명에서 14억 명으로 증가했습니다. 2050년 예측에 따르면 60세 이상 세계 인구는 두 배로 증가하여 21억 명에 달할 것으로 예상됩니다. 따라서 고령화 인구의 증가는 골다공증 치료제 시장의 성장을 촉진하는 중요한 요인으로 부상하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 골다공증 치료제 시장, 유형별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 비스포스포네이트
  • 선택적 에스트로겐 수용체 조절제(SERM)
  • RANK 리간드 억제제
  • 세계의 골다공증 치료제 시장, 투여별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 경구
  • 주사
  • 세계의 골다공증 치료제 시장, 유통 채널별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 소매 약국
  • 병원 약국
  • 온라인 판매
  • 세계의 골다공증 치료제 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 원발성 골다공증
  • 이차성 골다공증

제7장 지역 및 국가 분석

  • 세계의 골다공증 치료제 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 골다공증 치료제 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • 골다공증 치료제 시장 경쟁 상황
  • 골다공증 치료제 시장 기업 개요
    • Pfizer Inc.
    • F. Hoffmann La Roche Ltd.
    • Merck &Co. Inc.
    • Novartis AG
    • Bristol Myers Squibb Company

제31장 기타 주요 및 혁신적인 기업

  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Asahi Kasei Pharma Corporation
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • Daiichi Sankyo Company Limited
  • Union Chimique Belge
  • Sun Pharmaceutical Industries Ltd.
  • Ipsen
  • Kyowa Kirin Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.04.03

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be attributed to an aging population, heightened awareness and diagnosis, lifestyle factors, and government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The forecasted growth is driven by continuing trends of an aging population, advancements in treatment options, increased focus on men's bone health, patient education, and global health policies. Key trends include personalized medicine, exploration of combination therapies, emphasis on fracture prevention, research and development in novel drug targets, and collaborative efforts for drug development.

The increasing prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis, a bone disease characterized by a decline in bone mineral density and mass or changes in bone quality and structure, is often associated with low calcium intake. Osteoporosis drugs play a crucial role in increasing bone mineral density and preventing fractures in individuals affected by the condition. For example, as of May 2022, statistics from Amgen, a US-based biotechnology company, revealed that osteoporosis causes approximately 1.5 million fractures in the United States annually, resulting in associated costs amounting to $19 billion. Furthermore, the annual number of fractures caused by osteoporosis is projected to increase by 68% from 2018 to 2040, rising from 1.9 million to 3.2 million. Consequently, the surging prevalence of osteoporosis stands as a key factor driving the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In August 2021, Nestle Health Science, a Switzerland-based provider of nutrition solutions, diagnostics, devices, and drugs, successfully acquired the core brands of Bountiful Company for an undisclosed amount. This strategic acquisition is aimed at enhancing Nestle Health Science's portfolio with trusted products and methodologies, further advancing its mission to improve the health of clients globally. Bountiful Company, based in the United States, is recognized for its joint care supplement brand.

Major companies operating in the osteoporosis drugs market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Enzene Biosciences Ltd., Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Theramex, Radius Health Inc., Actavis PLC, Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2023. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
  • 2) By Administration: Oral; Injectable
  • 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
  • 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Osteoporosis Drugs Market Size and Growth

  • 5.1. Global Osteoporosis Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Osteoporosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Osteoporosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Osteoporosis Drugs Market Segmentation

  • 6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bisphosphonates
  • Selective Estrogen Receptor Modulators (SERMs)
  • RANK Ligand Inhibitors
  • 6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • 6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Sales
  • 6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Primary Osteoporosis
  • Secondary Osteoporosis

7. Osteoporosis Drugs Market Regional And Country Analysis

  • 7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

  • 8.1. Asia-Pacific Osteoporosis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Osteoporosis Drugs Market

  • 9.1. China Osteoporosis Drugs Market Overview
  • 9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Osteoporosis Drugs Market

  • 10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Osteoporosis Drugs Market

  • 11.1. Japan Osteoporosis Drugs Market Overview
  • 11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Osteoporosis Drugs Market

  • 12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Osteoporosis Drugs Market

  • 13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Osteoporosis Drugs Market

  • 14.1. South Korea Osteoporosis Drugs Market Overview
  • 14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Osteoporosis Drugs Market

  • 15.1. Western Europe Osteoporosis Drugs Market Overview
  • 15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Osteoporosis Drugs Market

  • 16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Osteoporosis Drugs Market

  • 17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Osteoporosis Drugs Market

  • 18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Osteoporosis Drugs Market

  • 19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Osteoporosis Drugs Market

  • 20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

  • 21.1. Eastern Europe Osteoporosis Drugs Market Overview
  • 21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Osteoporosis Drugs Market

  • 22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Osteoporosis Drugs Market

  • 23.1. North America Osteoporosis Drugs Market Overview
  • 23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Osteoporosis Drugs Market

  • 24.1. USA Osteoporosis Drugs Market Overview
  • 24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Osteoporosis Drugs Market

  • 25.1. Canada Osteoporosis Drugs Market Overview
  • 25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Osteoporosis Drugs Market

  • 26.1. South America Osteoporosis Drugs Market Overview
  • 26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Osteoporosis Drugs Market

  • 27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Osteoporosis Drugs Market

  • 28.1. Middle East Osteoporosis Drugs Market Overview
  • 28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Osteoporosis Drugs Market

  • 29.1. Africa Osteoporosis Drugs Market Overview
  • 29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Osteoporosis Drugs Market Competitive Landscape
  • 30.2. Osteoporosis Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Osteoporosis Drugs Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline PLC
  • 31.2. Eli Lilly and Company
  • 31.3. Amgen Inc.
  • 31.4. Novo Nordisk A/S
  • 31.5. Asahi Kasei Pharma Corporation
  • 31.6. Viatris Inc.
  • 31.7. Teva Pharmaceutical Industries Ltd
  • 31.8. Mylan N.V.
  • 31.9. Daiichi Sankyo Company Limited
  • 31.10. Union Chimique Belge
  • 31.11. Sun Pharmaceutical Industries Ltd.
  • 31.12. Ipsen
  • 31.13. Kyowa Kirin Co. Ltd.
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Osteoporosis Drugs Market Competitive Benchmarking

33. Global Osteoporosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market Future Outlook and Potential Analysis

  • 35.1 Osteoporosis Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Osteoporosis Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Osteoporosis Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제